pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Omlyclo
drug · antibody
save

omalizumab biosimilar

Marketedupdated 6mo ago
by Kashiv BioSciences LLC🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 6
  • drugomalizumab6 co-mentions · 4 sources
  • tagApproval4 co-mentions · 2 sources
  • drugOMLYCLO4 co-mentions · 2 sources
  • company$CAHCARDINAL HEALTH INC2 co-mentions · 2 sources
  • companyCelltrion Inc2 co-mentions · 2 sources
  • tagRecall2 co-mentions · 2 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 27 investigational indications.

indications

investigational
Asthma

targets

Immunoglobulin heavy constant epsilon

all catalysts(2)

approval · 2
Mar 7, 2025
approval
2y ago
OMLYCLO (OMALIZUMAB-IGEC) — FDA approval
omalizumab biosimilar
→
Dec 1, 2025
approval
12mo ago
OMLYCLO (OMALIZUMAB-IGEC) — FDA approval
omalizumab biosimilar
→

News(10)

  • Protein degrader specialist Lycia prices $318M IPO
    Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.
    biopharma_dive · 27d ago
  • Roche affirms sales outlook amid doubts about its future
    Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
    biopharma_dive · 28d ago
  • Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
    Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.
    biospace · 28d ago
  • Lycia aims for $228M IPO to generate data on food allergy rival to Xolair
    Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for autoimmune, inflammatory and allergic diseases.
    fiercebiotech · 1mo ago
  • An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
    Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
    biopharma_dive · 1mo ago
  • Celldex monoclonal antibody rebounds with pair of phase 3 wins for chronic skin condition
    Celldex touted a double phase 3 trial win in patients with treatment-refractory chronic spontaneous urticaria.
    fiercebiotech · 1mo ago
  • Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
    Cue Biopharma said Sunday its chronic hives candidate cleared a mid-stage trial, marking its first clinical data since its strategic pivot from cancer to immunology. In a Phase 2 China study in chr…
    endpoints · 1mo ago
  • Cue chalks up phase 2 hives win for Xolair challenger
    A midstage study of Cue Biopharma’s hives drug candidate has hit its primary endpoint, emboldening the biotech to move the would-be challenger to Xolair into a phase 2b/3 trial.
    fiercebiotech · 1mo ago
  • GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
    GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…
    fiercebiotech · 3mo ago
  • Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
    Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
    biospace · 3mo ago
view all news mentions →
brand
Omlyclo
trade names
Omlyclo, Xolair
generic
OMALIZUMAB-IGEC
MOA
Ig epsilon chain C region inhibitor
indication
Food Allergy
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 6h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?